Literature DB >> 32330687

Prognostic and clinicopathological significance of PD-L1 overexpression in oral squamous cell carcinoma: A systematic review and comprehensive meta-analysis.

Daniel Lenouvel1, Miguel Ángel González-Moles2, Isabel Ruiz-Ávila3, Lucia Gonzalez-Ruiz4, Isabel Gonzalez-Ruiz5, Pablo Ramos-García6.   

Abstract

BACKGROUND: The presence of Programmed Death-Ligand 1 protein (PD-L1) in oral squamous cell carcinoma (OSCC) may indicate an ability to evade immune response and has been suggested as a prognostic marker, but there is controversy in the literature.
OBJECTIVE: To review the scientific evidence of a prognostic role for PD-L1 levels in OSCC.
METHODS: PubMed, Embase, Web of Science, and Scopus were searched for studies published on or before March 02, 2019. Studies measuring PD-L1 levels by immunohistochemistry (IHC) in OSCC were included. Study quality was assessed using the QUIPS tool. Meta-analysis was performed for survival outcomes and clinic-pathological parameters.
RESULTS: 26 articles were included comprising 2532 patients. Analysis of studies measuring PD-L1 expression in the cell membrane showed a worse prognosis for disease-specific survival (HR = 1.74, 95% CI = 1.14-2.66, p = 0.01) and disease-free survival (HR = 1.56, 95% CI = 1.16-2.09, p = 0.003). PD-L1 overexpression was more likely in females (OR = 0.69, 95% CI = 0.53-0.91, p = 0.008), non-smokers (OR = 0.45, 95% CI = 0.27-0.75, p = 0.002), non-drinkers (OR = 0.40, 95% CI = 0.16-0.97, p = 0.04), advance stage tumours (OR = 1.63, 95% CI = 1.00-2.64, p = 0.05) and in tumours with high levels of PD-1 (OR = 33.36, 95% CI = 1.88-591.69, p = 0.02), CD4+ (OR = 3.25, 95% CI = 1.36-7.76, p = 0.008) and CD8+ (OR = 3.63 , 95% CI = 1.20-10.99, p = 0.02).
CONCLUSION: This meta-analysis found a worse prognosis in OSCCs overexpressing PD-L1 in the cell membrane as measured by disease specific survival and disease-free survival. We also found positive correlations between PD-L1 overexpression and advanced tumours, females, non-smokers, non-drinkers and high levels of tumour PD-1, CD4, and CD8.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  B7-H1 antigen; Immunohistochemistry; Meta-analysis [Publication Type]; Mouth neoplasms; Prognosis; Programmed death ligand 1; Squamous cell carcinoma of head and neck

Year:  2020        PMID: 32330687     DOI: 10.1016/j.oraloncology.2020.104722

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  19 in total

Review 1.  Age-specific oncogenic pathways in head and neck squamous cell carcinoma - are elderly a different subcategory?

Authors:  Martine Froukje van der Kamp; Gyorgy Bela Halmos; Victor Guryev; Peter Laszlo Horvatovich; Ed Schuuring; Bernardus Franciscus Augustinus Maria van der Laan; Bert van der Vegt; Boudewijn Evert Christiaan Plaat; Cornelia Johanna Verhoeven
Journal:  Cell Oncol (Dordr)       Date:  2022-01-11       Impact factor: 6.730

Review 2.  Hallmarks of Cancer Applied to Oral and Oropharyngeal Carcinogenesis: A Scoping Review of the Evidence Gaps Found in Published Systematic Reviews.

Authors:  Miguel Ángel González-Moles; Saman Warnakulasuriya; María López-Ansio; Pablo Ramos-García
Journal:  Cancers (Basel)       Date:  2022-08-08       Impact factor: 6.575

Review 3.  PD-L1 in oral squamous cell carcinoma: A key biomarker from the laboratory to the bedside.

Authors:  Riccardo Nocini; Matteo Vianini; Ilaria Girolami; Luca Calabrese; Aldo Scarpa; Maurizio Martini; Patrizia Morbini; Stefano Marletta; Matteo Brunelli; Gabriele Molteni; Anil Parwani; Liron Pantanowitz; Albino Eccher
Journal:  Clin Exp Dent Res       Date:  2022-05-20

4.  Frequency of Expression of PD-1 and PD-L1 In Head And Neck Squamous Cell Carcinoma And their Association With Nodal Metastasis: A Cross-Sectional Study.

Authors:  Iqraa Shakeel Malik; Muhammad Asif; Namrah Bashir; Nighat Ara; Farhat Rashid; Hafeez Ud Din; Numrah Shakeel Malik; Aimen Bashir
Journal:  Asian Pac J Cancer Prev       Date:  2022-02-01

5.  Association between programmed cell death ligand 1 expression and thyroid cancer: A meta-analysis.

Authors:  Baoyu Wan; Pengyi Deng; Wenli Dai; Peng Wang; Zhizhi Dong; Chaojun Yang; Jinling Tian; Tao Hu; Kai Yan
Journal:  Medicine (Baltimore)       Date:  2021-04-09       Impact factor: 1.817

6.  Increased Tumor Immune Microenvironment CD3+ and CD20+ Lymphocytes Predict a Better Prognosis in Oral Tongue Squamous Cell Carcinoma.

Authors:  Raísa Sales de Sá; Marisol Miranda Galvis; Bruno Augusto Linhares Almeida Mariz; Amanda Almeida Leite; Luciana Schultz; Oslei Paes Almeida; Alan Roger Santos-Silva; Clovis Antonio Lopes Pinto; Pablo Agustin Vargas; Kenneth John Gollob; Luiz Paulo Kowalski
Journal:  Front Cell Dev Biol       Date:  2021-02-18

7.  The Value of PD-L1 Expression in Predicting the Efficacy of Anti-PD-1 or Anti-PD-L1 Therapy in Patients with Cancer: A Systematic Review and Meta-Analysis.

Authors:  Xiao-Jiang Chen; Shu-Qiang Yuan; Jin-Ling Duan; Yong-Ming Chen; Shi Chen; Yun Wang; Yuan-Fang Li
Journal:  Dis Markers       Date:  2020-12-16       Impact factor: 3.434

8.  Positron Emission Tomography-Computed Tomography Parameters Predict Efficacy of Immunotherapy in Head and Neck Squamous Cell Carcinomas.

Authors:  Songtao Zhang; Runfang Zhang; Wenbo Gong; Chao Wang; Chen Zeng; Yifei Zhai; Qigen Fang; Liyuan Dai
Journal:  Front Oncol       Date:  2021-09-28       Impact factor: 6.244

Review 9.  Prognostic and Clinicopathological Significance of the Aberrant Expression of β-Catenin in Oral Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Pablo Ramos-García; Miguel Á González-Moles
Journal:  Cancers (Basel)       Date:  2022-01-18       Impact factor: 6.639

10.  Immune landscape and subtypes in primary resectable oral squamous cell carcinoma: prognostic significance and predictive of therapeutic response.

Authors:  Pengfei Diao; Yue Jiang; Yuanyuan Li; Xiang Wu; Jin Li; Chen Zhou; Lei Jiang; Wei Zhang; Enshi Yan; Ping Zhang; Xu Ding; Heming Wu; Hua Yuan; Jinhai Ye; Xiaomeng Song; Linzhong Wan; Yunong Wu; Hongbing Jiang; Yanling Wang; Jie Cheng
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.